-
Telling Their Stories Through PostersSurvivors and advocates display their posters alongside the work of thousands of cancer researchers.
by Kevin McLaughlin
-
The Crowded Field of Checkpoint InhibitorsDrug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
PARP Inhibitors in Pancreatic CancerDrugs that target DNA repair enzymes may provide alternatives to long-term chemotherapy for some patients with pancreatic cancer.
by Kate Yandell
-
Drug Costs and Cancer CareExperts discuss the value of cancer treatments in a climate of rising drug prices.
by Kevin McLaughlin
-
What Is Hyper-Progression?Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
Risk Reduction, Clinical Trials Are Focus of Atlanta Community EventCancer researchers, patient advocates and community members gathered for a public forum presented by the American Association for Cancer Research.
by Kevin McLaughlin
-
Sharing Knowledge, Building CommunityThe executive editor of Cancer Today previews the new issue.
by Kevin McLaughlin
-
What Not to Say to a Cancer PatientWhen visiting a friend or family member who is sick, it's good to leave platitudes at the door.
by Michael Gavaghen
-
First Immunotherapy Approved for Breast CancerMedical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
Holding Off on TreatmentPatients diagnosed with low-risk prostate cancer are increasingly opting against immediate surgery or radiation in favor of regularly monitoring their disease.
by Jon Kelvey
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to-treat cancer.
by Sandra Gordon
Bring On the WavesA surfer’s love for the ocean guides her through breast cancer treatment and beyond.
by Cameron Walker
Does Exercise Benefit Children With Cancer?New guidelines recommend children and adolescents with cancer get regular physical activity to mitigate side effects from treatment.
by Erin O’Donnell
Can the CYP2D6 Gene Affect Tamoxifen’s Effectiveness?A recent analysis examined whether CYP2D6 metabolism influences tamoxifen response. The answer isn’t entirely clear.
by Ashley P. Taylor
-
AACR OMB Statement and Call to ActionThe AACR is deeply concerned that proposed OMB regulations would disrupt federal research grant giving, severely weakening a program that has supported American medical innovation for decades.
-
AACR Cancer Disparities Progress ReportThe AACR Cancer Disparities Progress Report 2026 highlights recent progress in reducing cancer disparities and emphasizes the continued need for transformative research.
Cancer Research at a Crossroads
